Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Orforglipron cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Orforglipron has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Orforglipron combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Orforglipron cycle length?
No cycle is defined. Orforglipron is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Orforglipron?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Orforglipron dosing reference Full research page

References

  1. FOUNDAYO (orforglipron) tablets, for oral use, prescribing information (DailyMed SPL version 10, published Aug 13, 2026) FDA label (DailyMed). 2026
  2. Drugs@FDA application NDA 220934 (FOUNDAYO, Eli Lilly and Co; original approval 2026-04-01) via openFDA FDA (openFDA Drugs@FDA). 2026
  3. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist Proc Natl Acad Sci U S A. 2020
  4. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment N Engl J Med. 2025
  5. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes N Engl J Med. 2025
  6. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Lancet. 2026
  7. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial Lancet. 2026
  8. Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026
  9. PubChem compound record for orforglipron (CID 137319706) PubChem. 2026